Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19529545 | 0.87 | HTR1A (0.49) | IDO1DRD3HTR1APLAU | |
| SCHEMBL13049209 | 0.83 | IDO1 (0.52) | IDO1DRD3HTR1APRMT5WDR77 | |
| SCHEMBL22051969 | 0.83 | IDO1 (0.52) | IDO1DRD3PRMT5WDR77PLAU | |
| SCHEMBL8569330 | 0.79 | MTNR1A (0.49) | IDO1DRD3ALDH1A1 | |
| SCHEMBL8569332 | 0.79 | MTNR1A (0.49) | IDO1DRD3ALDH1A1 | |
| SCHEMBL8569327 | 0.79 | MTNR1A (0.49) | IDO1DRD3ALDH1A1 | |
| SCHEMBL23979090 | 0.79 | IDO1 (0.48) | IDO1DRD3PRMT5WDR77PLAU | |
| SCHEMBL19726333 | 0.78 | CTSD (0.36) | DRD3DRD2 | |
| SCHEMBL7255966 | 0.78 | IDO1 (0.56) | IDO1DRD3PRMT5WDR77PLAU | |
| SCHEMBL19726334 | 0.76 | FYN (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| EP-3247693-B1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON S.P.A. (IT) | 2017-12-21 | — | — | US | disclosed |
| EP-2463714-A1 | Basic compound, chemically amplified resist composition and patterning process | Shin-Etsu Chemical Co., Ltd. (JP) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | CYP3A5, SQLE, CYP3A4 | IDO1 14/4885DRD3 539/4885HTR1A 269/4885 |
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | IDO1 2105/4885DRD3 865/4885HTR1A 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.